Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants.

ABSTRACT:

Importance

People living with HIV and atrial fibrillation (AF) often receive anticoagulation that may interact with their antiretroviral therapy (ART). No studies exist comparing the safety of oral anticoagulants in this population.

Objective

To compare the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with AF and HIV.

Design, setting, and participants

A new-user, active-comparator, propensity score overlap-weighted cohort study using the target trial emulation framework including Medicare claims database data (January 1, 2013, to December 31, 2020) was carried out. The analysis was conducted from July 2023 to April 2024.

Exposure

New initiators of warfarin vs apixaban, rivaroxaban vs apixaban, and rivaroxaban vs warfari

SUBMITTER: Quinlan CM 

PROVIDER: S-EPMC11851300 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature